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Maternal diabetes is associated with increased risk of stillbirth (1 ) , but the causes are not fully clarified. Up to 40% of newborn infants of women with type 1 diabetes have echocardiographic signs of cardiomyopathy with cardiac enlargement and asymmetric septal hypertrophy. Most often, these changes are asymptomatic and disappear within the first 6 months of life, but they can also lead to severe morbidity and mortality (2) (3) (4) . It is thus conceivable that cardiac dysfunction could be a cause of stillbirths in pregnancies complicated by diabetes. During fetal life, infants of women with diabetes often have hyperglycemia, hyperinsulinemia (5, 6 ) , and increased concentrations of markers of hypoxic stress, e.g., plasma erythropoietin (5, 7 ) . These factors could all have negative effects on the fetal heart in utero (8, 9 ) . It is well established that optimal metabolic control at conception and during the first trimester is essential to minimize the risk of congenital malformations in the offspring (10 ) . In addition, suboptimal metabolic control in women with type 1 diabetes is associated with the risk of stillbirth (10 ) . Nevertheless, the strength of a putative association between metabolic control in the mother and the extent of neonatal hypertrophic cardiomyopathy is not known (11, 12 ) . At this stage, the diagnosis of neonatal diabetic cardiomyopathy is based on clinical observations and echocardiography.
B-Type natriuretic peptide (BNP) 4 is a 32-amino acid peptide produced in excess by cardiac myocytes during cardiac stress (13 ) . BNP is released as a 108-amino acid propeptide (proBNP), which is then cleaved into the active BNP (32 amino acids) and an N-terminal fragment (14 ) . The biological roles of BNP include regulation of the extracellular fluid volume and blood pressure by increasing natriuresis and inhibiting the renin-angiotensin-aldosterone axis. In the fetus, BNP functions as a vasodilator in the placental circulation (15 ) . BNP probably also has important protective autocrine effects in the heart by inhibiting fibrosis and hypertrophy (16 ) .
Plasma measurements of proBNP and BNP are now used to diagnose cardiac dysfunction in adults. The plasma concentrations of BNP and proBNP are increased in patients with heart failure, including those with hypertrophic cardiomyopathy (13, 17 ) . Children with congenital heart disease and newborns with severe fetal distress also have increased plasma BNP concentrations (18 -21 ) . However, it is unknown whether the plasma BNP or proBNP concentrations are affected in newborn infants of women with diabetes and thus may be markers of neonatal cardiomyopathy.
In this study, we measured umbilical cord blood BNP and proBNP concentrations in newborn infants of women with type I diabetes and controls. The results suggest that maternal diabetes is associated with increased secretion of proBNP from the fetal heart and that this effect is augmented by fetal stress during labor.
Patients and Methods patients
Thirty-seven pregnant women with type 1 diabetes and 23 healthy pregnant women were included in a prospective manner. Exclusion criteria were delivery before 34 weeks of gestation, preeclampsia, hypertension, and medically treated diseases other than type I diabetes. All women gave informed written consent, and the study protocol was approved by the local ethics committee (Ref. KF 01-048/-01). Basic data on the women, the course of labor, and the newborns were retrieved from medical charts and databases within the Department of Obstetrics.
Women with type 1 diabetes were divided into 2 groups according to their hemoglobin A 1c (Hb A 1c ) fraction before delivery. Arbitrarily, women with an Hb A 1c fraction below the median (6.2%) were considered in good metabolic control (5.2%-6.1%), whereas women with a fraction at or above the median were considered in suboptimal metabolic control (6.2%-7.2%). In the control group, the Hb A 1c fraction ranged from 5.0% to 5.9%. All pregnant women in our department are screened for gestational diabetes by a risk factor-based procedure (1 ) . Surprisingly, 1 woman in the control group had an Hb A 1c of 6.8%. The result was first recognized post partum, and her data were excluded.
plasma analysis
A venous blood sample for analysis of Hb A 1c by HPLC (22 ) was obtained from each mother before elective delivery (i.e., induction of labor or elective caesarian section) or when the women entered the labor ward in spontaneous labor. The umbilical cord was doubly clamped immediately after delivery, and arterial blood was drawn for measurement of pH. Umbilical venous blood for proBNP and BNP measurements was drawn into EDTA-containing tubes (1.5 g/L). The tubes were immediately placed on ice, centrifuged, and stored at Ϫ20°C for 1-3 days and then at Ϫ80°C until analysis. ProBNP was measured with a processing-independent assay in which trypsin digestion of the plasma proteins is used to release the NH 2 -terminal fragment of proBNP and its derived peptides before measurement by an RIA with antibodies directed against the NH 2 terminus of proBNP (23 ) . The intraassay CVs of the proBNP assay are 12% at 13 pmol/L, 7% at 75 pmol/L, and 5% at 130 pmol/L (n ϭ 10) (24 ) . BNP was measured with a commercially available immunoassay (Shionogi) that quantifies the bioactive BNP-32 peptide and has no cross-reactivity with atrial natriuretic peptide. According to the manufacturer, the intraassay CVs are 9.4% at 8.3 pmol/L and 12% at 168.9 pmol/L (25 ).
statistical analysis
Data are presented as the mean (SD) for gaussian-distributed variables and the median (interquartile range) for variables with a skewed distribution. Comparisons between groups were performed with ANOVA, followed by the Bonferroni multiple comparison tests where appropriate. Non-gaussian-distributed data were log-transformed before analysis. Associations between variables were examined with linear regression analysis. A 2-sided P Ͻ0.05 was considered statistically significant.
Results
To examine the impact of maternal diabetes on plasma proBNP and BNP concentrations in the infant, we collected venous umbilical cord blood from infants of women with type I diabetes and healthy controls. A priori, we decided to subdivide the women with diabetes into 2 subgroups based on the Hb A 1c fraction at term: Hb A 1c at or above the median value (6.2%) was considered as suboptimal metabolic control and Hb A 1c below the median as good metabolic control. Baseline variables were comparable in the 3 groups except for Hb A 1c , for which diabetic women in suboptimal metabolic control had the highest values, controls the lowest values, and diabetic women in good metabolic control were intermediate (Table 1) .
increased umbilical cord plasma proBNP in infants of women with suboptimally regulated type i diabetes
The proBNP plasma concentrations were significantly higher in cord blood from infants of women with type 1 diabetes and suboptimal metabolic control than in cord blood from infants born to control women ( Fig. 1A and Table 2 ). The median plasma proBNP concentration in infants of women with diabetes and good metabolic control was intermediate and did not differ significantly from the other groups ( Fig. 1A and Table 2 ). The plasma BNP concentration did not differ significantly among the 3 groups, although there was a trend toward a higher median concentration (P ϭ 0.08) in the infants of women with an Hb A 1c fraction above the median (Fig. 1B and Table 2 ). There was a strong association between plasma proBNP and BNP concentrations ( Fig. 1C ; r 2 ϭ 0.80 for log-transformed data; P Ͻ0.0001). The mean (SD) proBNP/BNP molar ratios were 8 (12), 6 (3), and 6 (5) in infants of control women and women with diabetes and good or suboptimal metabolic control, respectively.
Fifteen infants of healthy women (68%) vs 6 infants of women with diabetes (18%) were delivered by elective cesarean section (Table 2 ). To examine whether the method of delivery confounded the observed proBNP concentration difference between the diabetes and control groups, we stratified the infants according to method of delivery. The plasma proBNP concentration was increased to the same extent in infants of diabetic mothers whether they were delivered vaginally or by cesarean section (Fig. 2) . In a 2-way ANOVA with plasma proBNP as the dependent variable and diabetes and method of delivery as the independent variables, the effect of maternal diabetes was statistically significant (P ϭ 0.047), whereas the effect of the method of delivery was not (P ϭ 0.09). Of note, this analysis did not differentiate between women with suboptimal or good metabolic control because of the small number of patients in the study.
The gestational age was slightly lower and, as expected, the birth weight was higher in the diabetes group than in the control group (Table 2) . However, neither proBNP nor BNP concentrations were associated with gestational age or birth weight. association of umbilical cord plasma proBNP and BNP concentrations with perinatal stress On regression analyses, cord plasma concentrations of proBNP and BNP were positively associated with the duration of pushing in the second stage of labor and inversely associated with cord blood pH and Apgar score after 1 min in the infants of women with diabetes and suboptimal metabolic control (Table 3) . Within this group of infants, the cord plasma proBNP concentration was associated with maternal Hb A 1c at weeks 6 -10 of pregnancy but not with Hb A 1c at time of delivery (Table 3 ). In contrast, we did not see any associations between proBNP or BNP and the indexes of perinatal stress or Hb A 1c in infants of healthy women or women with diabetes and good metabolic control.
Discussion
The aim of this study was to assess the impact of maternal type I diabetes on production of proBNP and BNP in the fetus. When interpreting the results, it should be noted that we selected women with a relatively uncomplicated pregnancy by excluding pregnancies with preeclampsia or early preterm delivery. The results suggest that uncomplicated diabetic pregnancy is associated with increased plasma proBNP concentrations in the fetus and that proBNP and BNP concentrations tend to be higher when the mother is in suboptimal as opposed to good metabolic control.
As in plasma from adults with cardiac dysfunction (8 ), the umbilical cord plasma proBNP and BNP concentrations were closely associated. Nevertheless, the effect of maternal diabetes was more pronounced for proBNP than for BNP. The proBNP assay used in this study measures both intact proBNP and NH 2 -terminal fragments derived from this precursor, whereas the BNP assay measures only BNP-32 and not proBNP. We recently suggested that plasma proBNP is a more sensitive marker for acute cardiac stress than BNP, whereas proBNP and BNP probably have similar diagnostic sensitivities in chronic cardiac dysfunction (26 ) . Interestingly, the plasma proBNP/ BNP molar ratio in the newborns (mean ϳ6) was markedly higher than what is seen in adults [mean ϳ2.5 in patients with cardiac disease and ϳ1.1 in healthy individuals (8 ) ]. This may suggest that the conversion of proBNP to BNP is less efficient in fetal life than in adulthood, although the proposed proBNP-processing protease, corin, is secreted in large amounts in the fetal heart, at least in mice (27 ) . In addition, the difference in the ratio of proBNP to BNP may reflect differences in the rates of elimination of the NH 2 terminus of proBNP and BNP from plasma. The kidney is considered a major organ for removal of BNP. Thus, there might be differences in the handling of proBNP and its processing products between the fetal and adult kidney.
The murine placenta contains BNP mRNA in the peripheral margin of the decidual layer (28 ) . In this study, we examined BNP secretion in 3 term placentas from nondiabetic women (data not shown). We were unable to amplify the BNP mRNA transcript in any of 9 placental RNA preparations from the placentas with a real-time reverse transcription-PCR assay that easily detects BNP mRNA concentrations less than 1/1000th of those in adult human hearts (8 ) . Moreover, proBNP immunoreactivity was not detectable (Ͻ0.2 pmol/g of tissue) when protein extracts from the 3 placentas were examined with our proBNP immunoassay. These findings are compatible with the theory that increased proBNP concentrations in umbilical cord blood of infants of women with diabetes reflect increased secretion from the fetal heart rather than from the placenta. Previous studies have shown that severe perinatal stress causes an increase in umbilical cord plasma BNP and proBNP concentrations (19 ) . We therefore investigated whether the plasma proBNP and BNP concentrations were associated with measures of perinatal stress. Importantly, duration of pushing, umbilical cord blood pH, and Apgar scores were similar in the control and diabetes groups, suggesting that differences in fetal stress could not account for the present results. Nevertheless, 3 indicators of perinatal stress (i.e., duration of pushing, cord blood pH, and Apgar score after 1 min) all displayed significant correlations with plasma proBNP and BNP within the group of infants of women with diabetes and suboptimal metabolic control. In contrast, none of the indexes of perinatal stress were associated with proBNP or BNP in the control group or the group of infants of women with diabetes and good metabolic control. These findings could reflect that maternal diabetes causes dysfunction of the fetal heart that precipitates primarily when the fetal circulation is under stress. This "2-hit" hypothesis, that tissue dysfunction in metabolic diseases needs a second insult before it becomes manifest, has parallels in adult diabetic cardiomyopathy and liver dysfunction (29, 30 ) . Of note, poor metabolic control per se increases cardiac output by ϳ10% in adults with type 1 diabetes (31 ), and it is conceivable that the increase in fetal BNP secretion in infants of mothers with diabetes reflects increased pre-or afterload of the fetal heart, perhaps attributable to fetal hypervolemia.
In the infants of women with diabetes, the plasma In a 2-way ANOVA with plasma proBNP as the independent variable and diabetes and method of delivery as the dependent variables, the effect of maternal diabetes was statistically significant (P ϭ 0.047), whereas the effect of the method of delivery was not (P ϭ 0.089). proBNP concentration was more closely associated with Hb A 1c concentrations early in pregnancy than with Hb A 1c concentration at term. This finding could reflect that diabetes already imposes adverse effects on the fetal heart during its formation; however, it may also result from the fact that the larger variation in Hb A 1c at weeks 6 -10 yields more statistical power in the linear regression analysis.
Increased proBNP secretion in infants of women with diabetes may affect both the fetal circulation and have autocrine effects within the heart. The resistance in the placental vasculature is increased in maternal diabetes (32 ) . Infusion of BNP into the fetal-placental circulation of sheep leads to dilation of the placental vasculature (15, 33 ) . Thus, it is possible that increased proBNP secretion serves as a protective response and decreases the afterload on the fetal heart. It has recently become clear from studies of genetically modified mice that BNP (and atrial natriuretic peptide) in addition to its peripheral effects also has autocrine effects in the heart. Mice lacking either the BNP or the BNP receptor genes display cardiac fibrosis and hypertrophy (34 ) . It is therefore tempting to speculate that increased proBNP secretion also constitutes a local defense mechanism that counteracts the signals causing fetal cardiac hypertrophy when the mother has diabetes and is in suboptimal metabolic control.
In conclusion, our results indicate that the cord plasma proBNP concentration is increased in infants of women with type I diabetes and suboptimal metabolic control and that the increase in proBNP is accentuated during perinatal stress.
